来源：环球网 阿尔茨海默病作为神经退行性疾病，已成为威胁老年人健康的"第四大杀手"，是我国面临的重大公共卫 生挑战之一。签约仪式上，上海市中医老年医学研究所郁志华教授指出："我国现存阿尔茨海默病及其 他痴呆患者约1699万例，每年新发291万例。更值得注意的是，约75%的患者未能获得及时诊断，疾病 认知与就诊率低，为数千万家庭带来沉重照护负担。" 近年来，国家层面连续推出《应对老年期痴呆国家行动计划（2024-2030年）》及其他相关政策，并将 认知功能筛查纳入《成人健康体检项目推荐指引》，推动早筛早诊。这些举措不仅强化了疾病防控体 系，也为相关医药产品带来重要发展机遇。 在此背景下，沃华医药与宜从容携手，共同推动国内为数不多的、获批用于阿尔茨海默病治疗的中成药 ——参枝苓口服液，将更高效地服务于临床与患者。 【环球网财经综合报道】11月18日上午，山东沃华医药科技股份有限公司（以下简称"沃华医药"）与北 京宜从容科技有限公司（以下简称"宜从容"）在山东潍坊沃华医药举行"参枝苓口服液品牌共建战略合 作"签约仪式。沃华医药总裁、营销平台联席总经理李盛廷与宜从容总经理张小平代表双方签署协议。 （图说：沃华医药总裁 ...

11月18日上午，沃华医药（002107）与北京宜从容科技有限公司(以下简称"宜从容")在山东潍坊沃华医 药举行"参枝苓口服液品牌共建战略合作"签约仪式。沃华医药总裁、营销平台联席总经理李盛廷与宜从 容总经理张小平代表双方签署协议。 双方将整合研发、生产、临床推广与市场渠道资源，共同推动沃华医药独家专利产品——参枝苓口服液 在阿尔茨海默病防治领域的广泛应用，提升中成药在认知障碍全程管理中的临床价值。 上海市中医老年医学研究所党支部书记郁志华；潍坊生物医药产业园服务中心党委书记、主任张卫东， 党委委员戴曰慧，副主任刘继文；沃华医药党委书记、董事王炯，副总裁曾英姿；宜从容副总经理孙东 斌、王英勇，市场总监吴霞等嘉宾和各方媒体记者出席了签约仪式。 应对阿尔茨海默病，从疾病负担到政策机遇 阿尔茨海默病作为神经退行性疾病，是我国面临的重大公共卫生挑战之一。签约仪式上，上海市中医老 年医学研究所郁志华教授指出："我国现存阿尔茨海默病及其他痴呆患者约1699万例，每年新发291万 例。更值得注意的是，约75%的患者未能获得及时诊断，疾病认知与就诊率低，为数千万家庭带来沉重 照护负担。" 近年来，国家层面连续推出《应对老年期 ...

Core Points - Ping An Health Insurance, in collaboration with Peking University Medical Group and other partners, launched a public welfare initiative focused on Alzheimer's disease awareness and support [1] - The initiative aims to provide funding for Alzheimer's education, screening, and rehabilitation for elderly communities [1] - The project "Together Love - Alzheimer's Disease Support" was initiated in October 2024, emphasizing the company's commitment to community health [1] Group 1 - Ping An Health Insurance held the "Early Prevention and Early Treatment to Protect Cognition" event on September 22, coinciding with the first working day after the 32nd World Alzheimer's Day [1] - The company plans to continue its efforts in building a comprehensive service system for Alzheimer's disease that includes prevention, screening, diagnosis, rehabilitation, and care [1] - The initiative reflects the company's dedication to its "finance for the people" mission by leveraging resources in health insurance and medical services [1]

Group 1 - The core viewpoint of the news is that NuoVation has signed a cooperation agreement with Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. to develop a cell therapy project focused on Alzheimer's Disease, aiming to enhance early diagnosis and treatment options through technological innovation [1] - The collaboration will involve establishing a new biopharmaceutical company, with both NuoVation and Yimiao Shenzhou holding a 50% stake each, to facilitate further cooperation and specific business operations [1] - In 2024, NuoVation's revenue composition is projected to be 85.17% from research and experimental development, 14.66% from pharmaceutical manufacturing, and 0.17% from other businesses [1] Group 2 - As of the report, NuoVation's market capitalization is 9.7 billion yuan [2]

Core Viewpoint - The company, 诺唯赞 (688105.SH), has signed a cooperation development agreement with 北京艺妙神州生物医药股份有限公司 to collaborate on cell therapy projects targeting Alzheimer's Disease, aiming to enhance early diagnosis and treatment options through technological innovation [1] Group 1: Partnership Details - The agreement involves establishing a joint venture company, tentatively named 北京唯妙生物科技有限公司, with both companies holding a 50% stake [1] - The registered capital of the joint venture is set at RMB 40 million, with the company contributing RMB 20 million [1] Group 2: Project Objectives - The collaboration aims to leverage both parties' strengths in Alzheimer's screening and cell therapy to develop comprehensive prevention and treatment solutions [1] - The focus is on technological breakthroughs in early diagnosis and upgrading intervention plans to enhance the health and memory of the elderly population [1]

Core Viewpoint - Wanbond's subsidiary has obtained a patent for a novel composition aimed at treating Alzheimer's disease and skin photoaging, highlighting innovation in drug development [1] Group 1: Patent Acquisition - Wanbond's wholly-owned subsidiary, Wanbond Pharmaceutical Group Co., Ltd., has received an invention patent certificate from the National Intellectual Property Administration [1] - The patent is for a composition and formulation that combines ginseng, ginkgo biloba leaves, and a specific herb, representing a first-class new drug compound [1] Group 2: Product Characteristics - The patented composition is characterized by high safety, low dosage, simple drug composition, and improved efficacy compared to existing single-agent medications [1] - The innovative therapy integrates multiple components, targets, and pathways to intervene in the pathological network of Alzheimer's disease, offering a superior treatment option for patients [1]

Core Insights - The study indicates that maintaining a healthy lifestyle can significantly extend cognitive health lifespan by 4 to 5 years, even for individuals carrying the high-risk APOEε4 gene [1] Group 1: Research Findings - Over 10% of elderly individuals in China carry the APOEε4 allele, which increases the risk of cognitive impairment by 23% compared to the general population, with changes beginning in middle age [1] - The research involved a 15-year follow-up of 6,488 elderly individuals aged 65 and above, demonstrating the interaction between lifestyle choices and genetic risk factors [1][3] - The study emphasizes that lifestyle factors can influence the effectiveness of genetic predispositions on cognitive health [1] Group 2: Healthy Lifestyle Recommendations - Five key healthy lifestyle habits were identified: not smoking or having quit for over 10 years, abstaining from alcohol or having quit for over 10 years, consuming a diverse diet with at least 12 types of food daily, engaging in regular physical activity, and participating in cognitive social activities [2] - Elderly individuals with 4 to 5 of these healthy habits have a 27% lower risk of transitioning from cognitive health to cognitive impairment and a 43% lower risk of transitioning to death [2] - Even those with existing cognitive impairment have a 73% higher chance of reversing to cognitive health by adhering to these lifestyle habits [2] Group 3: Implications for Alzheimer's Disease Prevention - The findings shift the focus of Alzheimer's disease management from treatment to health maintenance, highlighting the importance of controllable factors over uncontrollable ones [3] - It is suggested that 45% of Alzheimer's cases could be prevented through various modifiable risk factors, and delaying the onset of the disease by one year could reduce prevention costs by over 40% [3] - Recommendations include integrating lifestyle interventions into public health services and enhancing education to dispel myths about dementia being unavoidable [3]